December 10, 2025
At this year’s ISPOR Europe 2025 conference in Glasgow, Marek Kortus and Tomasz Kluszczynski presented the research poster, “Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products (PDMPs) Across Europe,” on behalf of PPTA Europe.
The research reveals the highly variable reimbursement, pricing, and stockpiling frameworks applicable to PDMPs across European countries and how these differences shape patient access and supply stability. At the same time, the research illustrates why these unique therapies don’t always fit into existing frameworks and why tailored solutions are essential to safeguard patient access, especially against the backdrop of rising price pressure and soaring production costs. After all, PDMPs are complex therapies produced from a finite resource, namely human plasma. This calls for a shift in perspective and greater acknowledgement of the value and particularities of PDMPs within health care policies.
Conversations with attendees on-site focused on the need for greater policy alignment, recognition of PDMPs as essential plasma-dependent medicines, and examples of effective national practices that support equitable access.
PPTA looks forward to continuing this important research and translating the findings into concrete, evidence-based policy recommendations.
